ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

2025-02-06 13:46:07 ET

Summary

• ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market.
• Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients.
• ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030.
• With minimal risks and a strong competitive advantage, ADMA Biologics presents a compelling long-term investment opportunity, especially following the recent stock pullback.

...

Read the full article on Seeking Alpha

For further details see: